Adalvo’s purchase of Enzene’s Nplate biosimilar program extends it into biologics and moves Enzene toward a CDMO-only model.
Feature|Videos|July 22, 2025
Delivering What Matters, Together
Author(s)Mike Schaefers, Shiva Khalafpour
A new partnership between MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions is delivering streamlined ADC solutions that simplify the supply chain, accelerate patient access to vital treatments, and offer customers expert support.
In this video, industry leaders Mike Schaefers, Chief Commercial Officer at Simtra BioPharma Solutions, and Shiva Khalafpour, Head of CDMO Business at MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, discuss the objectives of a recent alliance between their companies.
Watch this video and learn more:
- The motivation and vision behind the MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions partnership
- How this alliance simplifies the supply chain for clients in the ADC space
- The specific benefits customers can expect from this integrated approach
- Insights into the seamless integration of supply chain departments between both companies
- The crucial role of project managers in ensuring the partnership’s success
- How the collaboration expedites patient access to life-saving ADC therapies
Related to this article
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
BMS and SystImmune’s bispecific ADC iza-bren nearly doubles progression-free survival in EGFR-mutated lung cancer, GSK and Hansoh’s B7-H3 ADC Ris-Rez extends progression-free survival in relapsed osteosarcoma, and Immatics’ TCR bispecific IMA402 posts a 32% response rate in PRAME-high tumors.
Phase 1b data at ESMO 2026 show the TCR-based T-cell engager produced durable responses in PRAME-high melanoma, with 91% of patients alive at one year in the recommended dose range.
In two small phase 1b trials, the half-life-extended bispecific antibody improved skin disease and reduced airway inflammation. Aclaris will move next into a Phase 2b trial in eosinophilic esophagitis.
Risvutatug rezetecan extended median progression-free survival to 5.5 months vs 1.4 months with chemotherapy in pretreated osteosarcoma.
Izalontamab brengitecan extended median progression-free survival to 11.1 months vs 5.7 months with chemotherapy after EGFR TKI failure.
Trending on BioPharm International
1
Adalvo Acquires Enzene’s Romiplostim Biosimilar Program for ITP
2
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
3
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
4
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
5